Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9454768 | 0.98 | GRIN2B (0.57) | GRIN2BLTA4HL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL3375958 | 0.98 | GRIN2B (0.60) | GRIN2BLTA4HL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL3371525 | 0.91 | GRIN2B (0.63) | GRIN2BLTA4HSLC6A2SLC6A4KDM4E | |
| SCHEMBL515999 | 0.89 | G6PC1 (0.54) | GRIN2BSLC6A2SLC6A4G6PC1ALDH1A1 | |
| SCHEMBL28410816 | 0.89 | G6PC1 (0.54) | GRIN2BSLC6A2SLC6A4G6PC1ALDH1A1 | |
| SCHEMBL7885548 | 0.89 | G6PC1 (0.54) | GRIN2BSLC6A2SLC6A4G6PC1ALDH1A1 | |
| SCHEMBL3373138 | 0.87 | SLC6A2 (0.51) | GRIN2BSLC6A2SLC6A4G6PC1ALDH1A1 | |
| SCHEMBL27687125 | 0.85 | GRIN2B (0.51) | GRIN2BLTA4HL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL13017781 | 0.85 | SLC6A2 (0.53) | GRIN2BSLC6A2SLC6A4G6PC1ALDH1A1 | |
| SCHEMBL3376642 | 0.84 | KMT2A (0.57) | GRIN2BLTA4HSLC6A2SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5256698-A | Binding neurotransmitters | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-10-26 | — | — | US | claimed |
| EP-0540576-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001449-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1992-02-06 | — | — | WO | claimed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-5256698-A | Binding neurotransmitters | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5256698-A | Binding neurotransmitters | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0540576-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-05-12 | — | — | EP | disclosed |
| EP-0540576-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001449-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1992001449-A1 | PSYCHOACTIVE DRUG AND TREATMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | GRIN2B 2059/4885LTA4H 487/4885L3MBTL1 3202/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | GRIN2B 2059/4885LTA4H 487/4885L3MBTL1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.